Compare EFC & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EFC | NVAX |
|---|---|---|
| Founded | 2007 | 1987 |
| Country | United States | United States |
| Employees | 500 | N/A |
| Industry | Real Estate | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.6B |
| IPO Year | N/A | 1996 |
| Metric | EFC | NVAX |
|---|---|---|
| Price | $12.70 | $8.37 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 5 | 9 |
| Target Price | ★ $14.55 | $11.33 |
| AVG Volume (30 Days) | 1.5M | ★ 3.4M |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | ★ 12.32% | N/A |
| EPS Growth | N/A | ★ 309.76 |
| EPS | N/A | ★ 2.58 |
| Revenue | N/A | ★ $1,123,479,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $43.05 | N/A |
| P/E Ratio | $9.50 | ★ $3.14 |
| Revenue Growth | N/A | ★ 64.69 |
| 52 Week Low | $11.28 | $5.80 |
| 52 Week High | $14.12 | $11.85 |
| Indicator | EFC | NVAX |
|---|---|---|
| Relative Strength Index (RSI) | 65.44 | 44.12 |
| Support Level | $12.37 | $8.09 |
| Resistance Level | $14.00 | $8.45 |
| Average True Range (ATR) | 0.22 | 0.41 |
| MACD | 0.14 | -0.02 |
| Stochastic Oscillator | 94.72 | 39.80 |
Ellington Financial Inc is a specialty finance company. Its primary investment objective is to generate attractive, risk-adjusted total returns for its shareholders by making investments. The company has two reportable segments; The Investment Portfolio Segment is focused on investing in a diverse array of financial assets, including residential and commercial mortgage loans, residential mortgage-backed securities, non-mortgage- and mortgage-related derivatives, debt and equity investments in loan origination companies, and other strategic investments, and The Longbridge Segment is focused on the origination and servicing of reverse mortgage loans. It acquires reverse mortgage loans both through its origination activities and through secondary market purchases.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.